Olink service with a fast turn-around time

Proximity Extension Assay (PEA) technology is the unique technology behind our Olink® Reveal, Target and Flex panels. It enables high-throughput, multiplex immunoassays of proteins using minimal volumes of serum, plasma, or almost any other type of biological sample. – get unique, actionable insights into the real-time biology underlying human health and disease.

Target 48

  • Human Cytokine
  • Human Immune-Surveillance
  • Mouse Cytokine
  • qPCR end point reading
  • Absolute Quantification

FLEX

  • > 200 pre-validated protein biomarkers to choose from
  • Create a pick-and-choose 5 to 30 plex panel
  • Flex-kits developed and quality controlled within ~3-5 weeks
  • Absolute or Relative Quantification

Target 96

  • Cardiometabolic
  • Cardiovascular II
  • Cardiovascular III
  • Inflammation
  • Neurology
  • Neuro-Exploratory
  • Oncology II
  • Oncology III
  • Immuno-Oncology
  • Immune Response
  • Organ Damage
  • Development
  • Cell Regulation
  • Metabolism
  • Mouse Exploratory
  • Relative Quantification

Reveal

  • > 1,000 Proteins
  • NGS end point reading
  • Relative quantification

Reveal: Revolutionizing High-Throughput Proteomics


Olink Reveal is the newest solution in high-throughput proteomics, leveraging Olink’s well-established Proximity Extension Assay (PEA) technology combined with next-generation sequencing (NGS) readouts. Similar to Olink Explore platform, Olink Reveal offers a refined assay library and a cost-efficient workflow and enables researchers to analyze over 1,000 proteins using just 4 µL of sample.

The Olink Reveal assay library is meticulously curated to provide:

  • Broad Pathway Coverage: Capturing 100% of major biological pathways from Reactome and 64% of all pathways, ensuring a comprehensive systems biology perspective.
  • Comprehensive Immune Response Profiling: Featuring 537 inflammatory markers, covering 96% of immune response pathways, enabling detailed insights into inflammation and immune regulation.
  • Genetic Linkage with cis-pQTLs: Including over 700 proteins with documented cis-pQTLs, genetic variants located near the encoding gene, offering key insights into disease mechanisms and genetic regulation of protein expression.
  • Disease Associations: Prioritizing proteins with the highest disease risk scores identified in the UK Biobank proteomics project, ensuring relevance for biomarker discovery and translational research.
    Key Benefits
    Olink Reveal delivers femtogram-per-milliliter (fg/mL) sensitivity with <8% CV between plates and across different sites. Demonstrating high correlation (R > 0.94) with Olink Explore and Target panels, it ensures data consistency and reliability.
    Its cost-effective workflow enables the simultaneous analysis of 86 samples across 1,000+ protein targets in a single run, making it an ideal tool for large cohort studies. By uncovering disease signatures and inflammation mechanisms, Olink Reveal facilitates groundbreaking discoveries in biomarker research.
    By integrating extensive pathway coverage with exceptional data quality in an accessible format, Olink Reveal transforms modern proteomics, empowering researchers to explore, understand, and drive advances in disease research. This platform is poised to accelerate biomarker discovery, paving the way for diagnostics and personalized medicine.

Olink Service by Ascend Biosciences

At Ascend Biosciences, we are dedicated to driving better health through innovation in proteomics. We are proud to incorporate Olink Target and Reveal into our portfolio, enabling researchers to harness the latest advancements in protein biomarker discovery.


By merging our deep multi-omics expertise with Olink’s groundbreaking platforms, we provide comprehensive solutions that accelerate disease research, support diagnostic assay development, and drive precision health forward.